Alivus Life Sciences (NSE:ALIVUS) Total Equity: ₹33,321 Mil (As of Mar. 2026)


NSE:ALIVUS Alivus Life Sciences Ltd NSE:ALIVUS
88 GF Score
Price ₹1,157.70
GF Value ₹1,006.57
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Alivus Life Sciences Total Equity?

Alivus Life Sciences NSE:ALIVUS -0.13% 88 Total Equity is ₹33,321 Mil as of Mar. 2026. GuruFocus rates NSE:ALIVUS with a GF Score™ of 88/100 and a GF Value™ of ₹1,006.57 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Alivus Life Sciences's total equity for the quarter that ended in Mar. 2026 was ₹33,321 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Alivus Life Sciences Total Equity Historical Data

* Premium members only.

The historical data trend for Alivus Life Sciences's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alivus Life Sciences Total Equity Chart

Alivus Life Sciences Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Equity
Get a 7-Day Free Trial 20,543.12 21,382.07 23,323.22 28,173.72 33,321.32

Alivus Life Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28,173.72 0.00 30,153.56 0.00 33,321.32
NSE:ALIVUS
88GF Score
Alivus Life Sciences Ltd NSE:ALIVUS
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alivus Life Sciences Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Alivus Life Sciences's Total Equity for the fiscal year that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=39828.97-6507.65
=33,321

Alivus Life Sciences's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=39828.97-6507.65
=33,321

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of ₹33,321 Mil mean?
Alivus Life Sciences (NSE:ALIVUS) has a Total Equity of ₹33,321 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Alivus Life Sciences and its competitors.
Is Alivus Life Sciences' Total Equity too high?
Alivus Life Sciences' current Total Equity is ₹33,321 Mil. Overall, Alivus Life Sciences has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alivus Life Sciences' Total Equity compare to ZTS and UTHR?
Alivus Life Sciences' Total Equity of ₹33,321 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Alivus Life Sciences and its competitors. Alivus Life Sciences's current Total Equity is ₹33,321 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alivus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Alivus Life Sciences (NSE:ALIVUS) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,006.57, compared to a current price of ₹1,157.70 — trading 15% above its estimated fair value. The current Total Equity is ₹33,321 Mil. Alivus Life Sciences' overall GF Score™ is 88/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Alivus Life Sciences (NSE:ALIVUS), the current Total Equity is ₹33,321 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alivus Life Sciences (NSE:ALIVUS) Overvalued in 2026?

Based on GuruFocus' analysis, Alivus Life Sciences stock appears to be overvalued. The current stock price of ₹1,157.70 is trading 15% above its estimated GF Value™ of ₹1,006.57. GuruFocus considers Alivus Life Sciences to be Modestly Overvalued.

Key valuation signals for NSE:ALIVUS:

  • Total Equity: ₹33,321 Mil
  • GF Value™: ₹1,006.57 vs. price of ₹1,157.70 (15% above fair value)
  • GF Score™: 88/100 with 5 warning signs

No single metric tells the full story. See the NSE:ALIVUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alivus Life Sciences Business Description

Other Exchanges 543322:India
Address 470, Cardinal Gracious Road, 4th Floor, OIA House, Andheri (East), Mumbai, MH, IND, 400 099
Alivus Life Sciences Ltd develops, manufactures, and supplies high-quality active pharmaceutical ingredients for cardiovascular disease, central nervous system disorders, pain management, diabetes, urology, gastrointestinal disorders, and other therapeutic areas.
88GF Score

Get the complete analysis for NSE:ALIVUS

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,157.70
Price
₹1,006.57
GF Value